LINC 2023: Late-breaking Science Video Collection
Published: 20 June 2023
-
Views:
1028 -
Likes:
7
-
Views:
1028 -
Likes:
7
-
Up Next
-
8m 56sPart 1 | Session 9 LIFE-BTK: Esprit BTK System in Narrowed Infrapopliteal Lesions
-
5m 2sPart 1 | Session 1 AVPAS: Lutonix AV Post-Approval Study Scott O Trerotola
-
5m 18sPart 1 | Session 2 The ELEGANCE Registry: Ranger DCB In Under-Represented Groups Marianne Brodmann
-
4m 51sPart 1 | Session 3 RANGER II SFA: 3 Year Patency and 4 Year Clinical Safety Marianne Brodmann
-
4m 48sPart 1 | Session 4 IN.PACT AV ACCESS: Outcomes to Date Matteo Tozzi
-
8m 14sPart 1 | Session 5 TINTIN: Combination DCB and Bare Metal Stents In PAD: 4 Year Outcomes Koen Deloose
-
7m 13sPart 1 | Session 6 POPCORN Registry: DCB Treatment for Peripheral Artery Disease Yoshimitsu Soga
-
3m 49sPart 1 | Session 7 MOTIV Bioresorbable Scaffold in BTK Lesions Michel Bosiers
Overview
Short, accessible Expert Interviews will be available with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Part 1
Expert Interviews
Short, accessible Expert Interviews with select faculty focusing on the results, applicability, and impact on future research.
About the episode
LINC 23 - Dr Marc Sirvent (General University Hospital of Granollers, ES) discusses his personal experience with the Cre8™ BTK polymer-free amphilimus-eluting stent in this short interview from LINC 2023.
Dr Sirvent outlines the clinical evidence surrounding this stent, and his unique experience with the use of this stent in infrapopliteal lesions.
Questions:
- Please tell us about the Cre8™ Stent and its features.
- Why did you start working with the device, and what unmet need does it address?
- What is the clinical evidence surrounding the Cre8 BTK Stent?
- What is your unique experience with this device, and what was the data released at LINC 23
- Where are the knowledge gaps, and what further study is needed?
Recorded remotely from Barcelona, 2023.
Editor: Jordan Rance
Video Specialist: Oliver Miles
Comments